Condition: Brain Tumors and/or Solid Tumors Including · Glioblastoma · Glioblastoma (GBM) · Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.
This description comes directly from the study's public registry record.
Francesco Di Meco, MD · + 39 02.2394 · francesco.dimeco@istituto-besta.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Neurologico Carlo Besta | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07420543